Cost-utility analysis of pacemakers for the treatment of vasovagal syncope.
Dual-chamber pacing is a promising treatment for patients with very frequent vasovagal syncope, but its cost utility is unknown. We report that the incremental cost per quality-adjusted life-year gained is $13,159 Canadian dollars (about $8,600 US dollars), and therefore this pacemaker therapy for vasovagal syncope has a favorable cost-utility ratio.
Mitton
C R
CR
Health Research Group, University of Calgary, Alberta, Canada.
Rose
M S
MS
Koshman
M L
ML
Sheldon
R S
RS
D000328:Adult; D002170:Canada; D002304:Cardiac Pacing, Artificial / Q000191:economics* / Q000706:statistics & numerical data; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D005260:Female; D006801:Humans; D008297:Male; D010138:Pacemaker, Artificial / Q000191:economics* / Q000706:statistics & numerical data; D011788:Quality of Life; D055502:Secondary Prevention; D019462:Syncope, Vasovagal / Q000191:economics* / Q000628:therapy*